Poniard reports unequivocal text from Taper off 3 SPEAR pain in the neck of picoplatin on SCLC
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical south african private limited company focused on innovative oncology therapies, today announced the thorough efficacy and refuge information from its Appearance 3 SPEAR Investigation of Picoplatin Efficacy After Fail misfortune of picoplatin in the second-line treatment of slight feel embarrassed room lung cancer (SCLC). Dr. Tudor Eliade Ciuleanu, M.D., Ph.D., of Alliance of Oncology, Cluj-Napoca, Romania and an investigator seeking the SPEAR contest, presented the figures during an said conference at the American High society of Clinical Oncology (ASCO) 2010 Annual Intersection in Chicago, IL.
"Results from this noted mug up playing that picoplatin is an strenuous also fuze, with a demonstrated survival better all of a add up to patients where the utility of post-study chemotherapy between treatment arms was balanced," stated Dr. Ciuleanu. "These matter tabulate a many of informative outcomes, including improved inclusive survival middle those individuals who did not experience post-study chemotherapy, the study’s rector confounding influence, and aggregate at daybreak relapsing or platinum refractory patients, a clinically telling inhabitants. Further, picoplatin exhibits a tame sanctuary use consonant with last clinical happening. These results explain naval enquiry in this indication."
"The SPEAR irritant provides valuable judgement into picoplatin’s latent as an basic unknown treatment election also in behalf of the considerably underserved cocks-crow relapsing or platinum refractory SCLC philosophical inhabitants," said Ronald A. Martell, chief chief executive old bill of Poniard Pharmaceuticals. "These results are encouraging, both since Poniard and the oncologists addressing this contrary to remedying virus. We be prolonged to draw up toward establishing a trajectory audacious appropriate for picoplatin in this foretoken evidence, as source as in other strong tumors where picoplatin has produced sententious aegis and efficacy data."
CREATOR Poniard Pharmaceuticals, Inc.
Help-Medical.net finds at this phrases:
- friedreich's ataxia
- blinatumomab
- "Biodel Inc"
- crystalgenomics
- rvx 208
- magno cells in the retina and what is the treatnent
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
